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ABSTRACT OF THE THESIS
ENHANCED FLEXIBLE MATERIALS FOR HEART VALVE PROSTHESIS
APPLICATIONS
by
Makensley Lordeus
Florida International University, 2015
Miami, Florida
Professor Sharan Ramaswamy, Major Professor
While mechanical, homograft and bio-prosthetic valves have been used in patients for
many decades and have made significant improvements in patient morbidity, there is still
a distinct need to overcome their limitations. Recently, emerging elastomer heart valves
have been shown to be able to better re-create the flow physics of native heart valves,
resulting in preferable hemodynamic responses. Unfortunately, elastomers such as
silicone are prone to structural failure, which drastically limits their applicability towards
the development of valve prosthesis. In order to produce a mechanically more robust
silicone substrate, we reinforced it with graphene nanoplatelets (GNPs). Cytotoxicity and
hemocompatibility tests revealed that the incorporation of GNPs did not adversely affect
cell proliferation or augment adhesion of platelets on the surface of the composite
materials. The ECM valves showed good hydrodynamic properties and favorable acute
performance compared to a commercially available valve. We conclude that both the
Graphene reinforce silicone and the ECM is useful and warrants further evaluation as
aortic valve substitutes.
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Chapter 1 Introduction
Heart valves promote coordinated forward blood flow during the cardiac cycle. These
valves have leaflets that open and close with each heartbeat. Valve disease such as
critical stenosis or regurgitation, is a significant public health problem (Hoffman &
Kaplan, 2002). Valve disease results in approximately 20,000 deaths annually. The direct
cost for valve disease in the United States alone has been estimated at $1 billion per year
(Hinton & Yutzey, 2011). Any one of the four heart valves can be affected; however, the
aortic and mitral valves are the most common for disease. In addition congenital valvular
disease such as aortic valve malformation is present in roughly 1 to 2% of the general
population (William C. Roberts & Ko, 2005).
Typically, when heart valves fail, they are replaced with a heart valve prosthesis.
Commercially available heart valve prostheses are divided into two categories:
mechanical and bio-prosthetic or tissue heart valves. Mechanical valves include caged
ball, tilting disc, and hinged bileaflet valves. Tissue valves include aortic homograft,
stent-mounted porcine heterograft and valves fabricated from bovine pericardium.
Mechanical heart valves are extremely durable. The FDA requires heart valves to
withstand 10 years of use (Food and Drug Administration, 2010), but there have been
cases where the mechanical heart valve has lasted for decades (Emery et al., 2005). These
valves are made with very strong materials, such as titanium, Teflon, and pyrolytic
carbon. The major problem with mechanical heart valve is thrombus formation. These
clots could result in very serious consequences, such as stenosis and myocardia
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infractions as well as present a danger for stroke. To prevent thrombus, the patient must
undergo anticoagulant therapy for the rest of their lives. The anticoagulant therapy may
results in other complications, such as bleeding and spontaneous abortions (John & Liao,
2013).
Tissue heart valves are made from animal tissues, such as cow pericardium and pig
valves. These valves are treated chemically (fixed with glutaraldehyde) to make the valve
inert and reduce the risk of an immune response. The resulting valve is very similar to a
human valve and exhibits much better hemodynamics than a mechanical valve. The
improved fluid dynamics of the valve decreases the chances of thrombosis and its native
tissue structure eliminates the need for anticoagulant therapy (Grunkemeier &
Rahimtoola, 1990). Unfortunately, these tissue valves have limited durability.
Elastomeric heart valves are made from elastomer materials that exhibit similar flexure
properties as the native heart valves (Ramaswamy et al., 2013). These heart valve are
designed to mimic the human native heart valve and recreate the flow dynamics. One
example is a silicone heart valve, which exhibits amazing flow dynamics, but like tissue
valves, are not very durable.
Significance
While mechanical, homograft and bio-prosthetic valves have been used in patients for
many decades and have made significant improvements in patient morbidity, there is still
a distinct need to overcome their limitations as evidenced by the ten-year mortality rate
following valve replacement, which ranges from 30 to 55% (Edmunds et al., 1997).
Research in the use of polymer materials for the fabrication of tri-leaflet valves has been
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ongoing for over 50 years, but has faced substantial hurdles in the facilitation of adequate
valve durability. However, new methods in manufacturing and reinforcement of polymer
materials have resurrected the appeal of polymer materials for heart valve prosthesis
application. One such material that has found renewed interest is silicone. Unfortunately,
silicone is prone to structural failure which drastically limits its applicability for heart
valve prosthetics (Roe, Kelly, Myers, & Moore, 1966).
Tissue heart valves also suffer from durability issues, but for reasons associated to
depletion of extracellular matrix components such as glycosaminoglycan (GAGs). Tissue
valves are much more analogous to native heart valves. They are able to last 5 to 10 years
implanted in the body before they fail. This is a huge issue for younger patients that
would have to undergo surgery again when the valve fails. Bioprosthetic heart valves fail
because of material deterioration and associated calcium phosphate deposits at the high
stressed areas. Substantial research has gone into investigating disruption of the
extracellular matrix (ECM), especially type I collagen fibrils. Loss of GAGs in heart
valves has only recently been under the spotlight for its link with tissue degradation.
Research has shown that GAGs leach out under accelerated fatigue irrespective of
bioprosthetic heart valves being fixed with glutaraldehyde crosslinking (Vyavahare et al.,
1999). One cause of failure of the bioprosthetic valve is adverse changes in mechanical
properties during degradation of the ECM. When the valves degrade, they become stiff
and the hydrodynamic properties are significantly hindered, which may also lead to
thrombosis and stenosis. One of the functions of GAGs is the maintenance of tissue
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hydration. Loss of GAGs leads to water loss in the valve tissue, which in turn, leads to
stiffening of the leaflets.
It is evident that with current technology, we do not from a materials property standpoint,
match silicone elastomer and native, chemically fixed tissues to the considerably more
durable mechanical valves properties. On the hand as already described, mechanical
valves still require life-long anticoagulant therapy, which precludes usage in subpopulation groups such as children, women who may wish to have children and
individuals who do not tolerate blood-thinners.
Notably, about 50-60% of patients with replacement valves either need a reoperation or die within ten years of valve implantation (A. Wang & Bashore, 2009). To
reduce these numbers, less invasive strategies for valve replacement such as percutaneous
valve approaches, which are still relatively new, are currently being considered in
patients at high-risk for open-heart surgery. The valves available currently for
percutaneous approaches all are made using pericardium tissue valves. Stemming from its
flexible characteristics, silicone valves would serve as a potential candidate for
percutaneous valve replacement. As noted, even when deployed in a minimally invasive
manner, pericardium valves are intrinsically not very durable and thus this limitation will
remain in percutaneous valve technologies.
Here we proposed that silicone could be reinforced with graphene nanoplatelets (GNPs)
to promote its strength and durability for subsequent valve prostheses development.
Graphene is known for its high-strength (Lee, Wei, Kysar, & Hone, 2008). Human cells
also exhibit a minimal cytotoxic response to graphene (Santos et al., 2012). The primary
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objective therefore was to characterize the response of silicone substrates to static and
cyclical loading conditions with and without graphene reinforcement and, in addition, to
assess whether the graphene-silicone composites had altered cytotoxicity and platelet
adhesion properties relative to the silicone substrate alone.
We were also interested in investigating the prosthetic valves made of an ECM
‘bioscaffold’ material. The ECM material is manufactured by commercial vendors (e.g.
CorMatrix, Roswell, GA) and acts as an acellular bioscaffold that is able to allow the
patients cells to populate and remold the tissue. The material is produced from porcine
small intestinal submucosa (SIS), which is located between the mucosal and muscular
layers of the small intestine. The SIS is removed and decelluarized, leaving the ECM
intact. These valves have already been implanted into newborn patients with critical
valvular defects (i.e., compassionate care cases) by doctors at Joe DiMaggio Children’s
Hospital (Holywood, FL) that we are collaborating with; over a year later, the valves are
still functioning flawlessly and the patients are doing well. Therefore, with the wealth of
clinical data that the doctors have combined with the hydrodynamic data that could be
obtained in vitro, it may be possible to further optimize functionality of the ECM valves.
The objective of my thesis is to identify protocols and processes that would offer
potential alternative solutions to existing limitations in current, commercially available
valve technologies
Thus in the area of emerging valve replacement technologies, we hereby propose
examining enhanced elastomeric materials for the valve application and further
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characterizing the functional properties of ECM valves currently being used clinically on
a controlled and limited basis.
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Chapter 2 Specific Aims
Specific Aim 1: Develop and characterize a graphene reinforce silicone material for
potential application in valve prosthesis development.
Specific aim 2: Analysis of ECM valve hydrodynamic properties and co-relation to
clinical data in the aortic and mitral valvular positions.
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Chapter 3 Literature Review
Heart Valves
There are four valves situated in the heart; the tricuspid and pulmonary valves on the
right-sided heart chambers and the mitral and aortic valves on the left-sided heart
chambers. Morphologically, these valves are divided into two atrioventricular (mitral and
tricuspid) and two semilunar (pulmonary and aortic valves(Dominik & Zacek, 2010). The
normal location could be seen in Figure 1.

Figure 1: Topographic interrelations of the heart valve. (Dominik & Zacek, 2010)
The aortic valve is situated in the left ventricular outflow tract and consists of three
semilunar cusps and their adjacent sinuses of Valsalva. The aortic valve does not have an
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anatomically defined annulus. The mitral valve is a bileaflet atrioventricular, located
between the left atrium and the left ventricle. The triscupid valve is situated between the
right atrium and the right ventricle and prevents back flow into the right atrium. The
pulmonary valve is a tricuspid semilunar valve in the right ventricular outflow tract. The
sinus and leaflets are similar to the aortic valve, but thinner (Dominik & Zacek, 2010).
Valvular Diseases – Aortic valve stenosis
After systemic hypertension and coronary heart disease, aortic stenosis is the third most
fatal heart disease(William Clifford Roberts & Ko, 2009). The three major causes of
aortic stenosis are atherosclerosis, congenitally malformed valves, and rheumatic heart
disease.
Aortic stenosis is a disease in which there is a progressive narrowing of the aortic valve
opening causing obstruction to the left ventricular outflow. This leads to an increase in
pressure in the left ventricular outflow. The most common location of artic stenosis is at
the valve as seen in Figure 2.

Figure 2: Gross pathological specimens from patients with aortic stenosis. (A. Wang &
Bashore, 2009)
The most common congenital heart disease is bicuspid aortic valve, occurring in
approximately 2% of the population. Bicuspid aortic valve stenosis is the most common
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reason for aortic valve replacement in patients under the age of 70. The most common
cause of aortic stenosis in older patients is senile degenerative aortic stenosis due to
degenerative changes with calcific deposits at the base of the aortic valve cusps.
When the stenosis reaches a critical level, the left ventricle is overwhelmed by the high
afterload and systolic function begins to decrease. Further afterload excess, myocyte
degeneration and fibrosis begin to occur, leading to irreversible left ventricular systolic
dysfunction. Even with severe obstruction, many patients with aortic valve stenosis may
remain asymptomatic for many years. Symptoms such as angina, dyspnea, and syncope
start to appear after a long latent period. The ACC/AHA Valvular Heart Disease
guidelines committee have defined the criteria for severity of aortic stenosis based on
hemodynamics (Table 1)
Table 1: Severity of stenosis based on hemodynamics
Severity of aortic
stenosis
Mild

Aortic valve
area (cm2 )
>1.5

Mean gradient
(mmHg)
<25

Peak velocity (m/s)
<3.0

Moderate

1–1.5

25–40

3.0–4.0

Severe

<1.0

>40

>4.0

Critical

<0.6

>60

>5.0

Valvular Diseases – Mitral Valve regurgitation and prolapse
Out of the heart’s 4 valves, the mitral is the most complex and the one most commonly
associated with diseases. The valve could be affected by 3 main types of conditions,
stenosis, regurgitation, and prolapse. Unlike the aortic valve, stenosis is the least common
of the 3 in the mitral valves, accounting for less than 1% of the cardiac diagnoses in the
United States (Turi, 2004). In mitral regurgitation, the valve does not seal completely
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during contraction of the left ventricle and blood leaks from the ventricle to the atrium.
One typical cause of regurgitation is enlargement of the left ventricle, where the ring of
the mitral valve is stretched, resulting in the leaflets not closing adequately.
Valve prolapse is the most common type of mitral valve diseases. It accounts for about
5% of the population, occurring most frequently in women. In prolapse, the leaflets of the
mitral valve bulges backwards during valve closure, see Figure 3. Mitral valve prolapse is
caused by valvular abnormalities of valvar tissue, geometric disparities between the left
ventricle and mitral valve, or various connective tissue disorders. A vast majority of
patients with mitral valve prolapse has normal life expectancy and have no long-term
medical problems associated with the condition. There is a small subset of patients that
develop serious complications, such as infective endocarditis, sudden cardiac death, and
severe mitral regurgitation (Hayek, Gring, & Griffin, 2005)
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Figure 3: The heart in systole. A) in normal individuals. B) in patients with both prolapse
and mitral regurgitation. (Turi, 2004)

Heart Valve Prostheses
There are two main types of artificial heart valves available commercially. The first
category is mechanical valves that are assembled from hard plastic materials, titanium or
other metallic alloys. The other category is biological valves that originate from
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biological tissue and which are chemically treated with gluteradehyde to render the tissue
inert.
Hemodynamically, the effective orifice area (EOA) is the most important parameter of
both mechanical and bioprostheic valves. The effective orifice area is different from the
geometric orifice area (GOA) , see Figure 4, which is the whole inner area of the valve
including the space that contains the leaflets, struts, and other mechanisms of the valve.
The EOA is the portion of the valve that blood really flows through. The effective orifice
area is usually one quarter or one third smaller than the geometric orifice area.

Figure 4: EOA in comparison with GOA. A) a rigid sharp-edged aortic stenosis; B) a
funnel-shaped aortic stenosis (Garcia & Kadem, 2006)
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Mechanical heart valves were the first developed and implanted in patients in the 1960s
and are constantly developed and refined to improve hemodynamic and biocompatibility.
There are three main types of mechanical valves: caged-ball, disc, and bileaflet valves.
The Starr-Edwards valve is the most well-known caged-ball valve. The 6120 and 1260
models were developed in the late 1960s as mitral and aortic valves, respectively. They
are still being manufactured without any modifications and were implanted until 2007
(Mann, Zipes, Libby, Bonow, & Braunwald, 2014). Patients that were fitted with a ball
and cage valve showed hemodynamic improvements but they suffered from very frequent
thromboembolic complications. To reduce the complications, caged valves were
developed with cloth covers. After several weeks or month after implantation endothelial
cells grew within the cover allowing the valve to be endothelialized, resulting in the
blood not coming into contact with a foreign surface (except the ball). However, several
years later, the cloth would tear, which would then initiate thrombus formation. This led
to significant hemolysis and reoperations to replace the artificial valve.
Disc valves were also introduced in the 1960s after the ball and cage valves. The first
ones were non-tilting disc valves, which had a low profile design, making them easier to
implant and have very little regurgitation. Unfortunately, the valves had very high flow
gradients and significant turbulence, which lead to frequent thromboembolic
complications and high hemolysis. These valves were replaced by modern tilting disc
valves. The tilting mono disc valves were the most frequently implanted valves in the
1970s and 1980s. The Medtronic-Hall valve is the most frequently implanted disc valve
worldwide and has been used clinically without modifications since 1977. Since the mid-
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1980s, the mechanical bileaflet valves have become the most frequently implanted valves
in the world, especially the St. Jude Medial valve.
Biological valves were developed to reduce the risk of serious hemocompatibility
complications that are associated with mechanical heart valves, such as thrombosis,
embolism, and excess bleeding. The most frequently implanted tissue valves are
xenografts. Xenografts are prepared from the tissues of other species. They are usually
mounted on a cloth-covered stent, which could be made from stellite, titanium, or plastic.
The stent could be slightly flexibly to absorb stress and prolong the xenograft’s
durability, and is covered in Teflon or polypropylene. The valves either are porcine aortic
valves or assembled from bovine pericardium. The valves are usually processed with a
proprietary treatment and stored in glutaraldehyde.
Stentless bioprostheses were introduced in 1988 and implanted in the aortic position.
They don’t have a stent or a sewing cuff. Stentless bioprosthetic valves allow a larger
valve to be implanted than would be possible with a stented valve, resulting in a larger
EOA. Stentless bioprosthetic valves have shown superior hemodynamic features and
more complete regression of left ventricular hypertrophy(Jin, 2002; Westaby et al.,
2000). Research data has proved no superiority of the stentless valves over stented valves
in long-term studies, particularly randomized clinical trials(Ali et al., 2007; Bové et al.,
2006; Cohen et al., 2002; Desai & Lodge, 2009).
Allografts are another option for tissue valves implantations. Allografts are harvested
from human cadaver aortic valves. The explanted allograft valves are treated with
antibiotic solution and frozen in stored in liquid nitrogen for up to 5 years. When the
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valve is defrosted, viable fibroblast is present but the endothelium is not preserved. The
lack of an endothelium reduces the allograft antigenicity and eliminates the need for
immunosuppression after implantation. Allografts are more difficult to implant and have
similar rates of degeneration as bioprosthetics, so they are used infrequently. Allografts
are less susceptible to infection than bioprosthetics and mechanical valves and are used
mostly for aortic valve replacement for infective endocarditis (O’Brien et al., 2001).
Autograft biological tissue could also be used for valve replacements. The Ross
procedure involves the replacement of the aortic valve with a patient’s own pulmonary
valve. An allograft pulmonary valve is used to substitute the original pulmonary valve.
The Ross procedure presents as currently the only approved procedure wherein a living
valve substitute is used.

However, controversies related to removal of a healthy

pulmonary valve have contributed to heightened research in tissue engineering of heart
valves, currently an active research area.
Materials Selection
As mentioned, mechanical valves, made with metals and hard plastics, offer superior
durability, while bioprosthetic valves, made of porcine and bovine tissue, offer favorable
hemodynamics. Synthetic elastomeric materials allow the possibility of engineering a
material to provide the best of both of these types of valves. Polyolefin (Kidane et al.,
2009) and nonreinforced silicone (Kiraly et al., 1982) have been tested as leaflet
materials which function very well, but ultimately show inadequate durability.
Polytetrafluoroethylene (PTFE), commonly known as Teflon, is a highly crystalline
fluorinated homochain polymer (Fox & Zisman, 1950). It is known for its inertness and
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low surface energy due to the strengths of the C-C and C-F bonds. This usually leads to
good biocompatibility, which is why PTFE could be found in many biomedical devices.
But valves made of PTFE have shown acute thrombosis and macroscopic calcification in
the commissural areas(Nistal et al., 1990). A tricuspid valve made of PTFE fabric was
made and implanted in 23 patients (Braunwald & Morrow, 1965). 13 of the patients
required reoperation. The valves failed due to stiffening, tearing, and some calcification.
Research into polyurethanes have resulted in a flexible and mechanically strong material,
but animal studies found degradation of the polyurethane surface structure, which was
accelerated by calcified material penetration the polymer (Kolff & Yu, 1989; Wheatley et
al., 2000).
Poly(styrene-b-isobutylene-b-styrene), known as SIBS, has also been investigated for
heart valve applications. SIBS is a biostable thermoplastic elastomer that has mechanical
properties in between silicone and polyurethane and is highly degradation resistant
(Pinchuk et al., 2008). SIBS impregnated in a Polyethylene terephtalate (PETE) mesh
showed no significant difference in thrombogenicity in a ventricular assist device
compared to mechanical and bioprosthetic valves (Yin et al., 2005). However, in a 20week in vivo study conducted in Ovine, surgically implantable valves had calcification
and thrombogenic responses (Q. Wang et al., 2010).
Graphene Nanoparticles
The modification of graphitic fillers usually enhances their interfacial interaction with
elastomer chains, thereby leading to better properties. The nanodimension and aspect
ratio of graphene make it’s elastomer nanocomposites superior to all other graphitic
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derived composites, provided robust dispersion of the filler is achieved (Sadasivuni,
Ponnamma, Thomas, & Grohens, 2014).
Though the conventional direct blending method provides sufficient torque to disperse
the fillers in rubber matrices, the high viscosity of the material often causes non-uniform
dispersion of the graphite platelets. Solution mixing has been widely reported as an
effective fabrication technique due to the ease of processing graphite derivatives and
graphene in water or organic solvents(Lian et al., 2011). The colloidal suspensions of
graphene-based materials are mixed with the desired elastomer by simple stirring or shear
mixing, (Figure 5). Sonication is often employed to better disperse the graphitic fillers.
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Figure 5: Frabrication of nanocomposite membrane. (Lian et al., 2011)
Polymer composites containing graphene possess good thermal conductivity and
mechanical stiffness(Fan et al., 2010). Graphene nanoplatelets have been shown to have
out-performed carbon nanotubes as a reinforced additive at low filler content of 0.1%
(Rafiee et al., 2009).
In a study where graphene/chitosan composite films were fabricated, it was found that
graphene significantly increased the modulus of chitosan at very low content, between
0.1 to 0.3%, as seen in Figure 6. The composites showed good biocompatibility for L929
cells, as confirmed by in vitro MTT assays(Fan et al., 2010).
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Figure 6: Load vs displacement curves of graphene/chitosan composites with different
amounts of graphene. (Fan et al., 2010)

ECM in Heart Valves
Porcine small intestinal submucosa (SIS) is an acellular matrix from the jejunum; it is
commonly used as a xenograft material. SIS has shown to be biocompatible and infection
resistant, possess predictable mechanical properties prior to implantation. It induces
tissue-specific remodeling responses in the organ or tissue into which it is placed rather
than nonspecific scar tissue (Badylak et al., 1995).
Porcine SIS has been shown to replace mature pulmonary valve leaflets in pigs (Matheny,
Hutchison, Dryden, Michael, & Shaar, 2000). Histopathological analysis of the explanted
leaflets revealed progressive replacement with fibrous connective tissue and
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microvasculature similar to mature host tissue. There was also a progression of
endothelialization of all the substitute leaflet surfaces with time.
Another study investigated the placement of a percutaneous low-profile prosthetic SIS
valve in the pulmonary position in 12 female pigs (Ruiz et al., 2005). Within 1 month, the
surface was covered by endothelium, and fibroblasts had invaded the interior, as seen in
Figure 7. Over the following months, the valve remodeled without apparent graft
rejection.

Figure 7: A, SIS 1 day after implantation, hematoxylin and eosin staining. B, 3 months
after implantation. C, 6 months after implantation. D, 12 Months after implantation. E,
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Native valve. F-H, SIS Valve 12 months after implantation with antibody staining. F,
subendothelial von Willebrand factor VIII. G, interstitial smooth muscle cells. H,
connective tissue vimentin. (Ruiz et al., 2005).
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Chapter 4 AIM 1: Graphene Reinforced Silicone
Heart Valve disease is a prevalent clinical problem in the United States. Current options
for heart valve replacement include mechanical valves, homograft, and bio-prosthetic
valves. Patients with mechanical heart valves however have to take lifelong
anticoagulants to prevent risk of thrombus. The down side to these valves is a high risk
for fibrosis, calcification, degeneration, and immunogenic complications that may lead to
failure in the valve.
Elastomers such as silicone have previously been used to create prosthetic heart valves
due to their similarity to native tissue, but are still prone to early structural failure
including leaflet tearing. We have incorporated graphene nanoplatelets into the silicone
matrix materials. The following study is presented as published in the Journal of Long
Term Effects of Medical Implants (Lordeus et al., 2015).

Introduction
Heart valve disease is characterized by the inability of native heart valves to continue
facilitating adequate forward blood flow from the myocardium. When one of the heart
valves fail, it can be replaced with an artificial heart valve. Current options for heart
valve replacement include: mechanical valves, homograft, and bio-prosthetic valves.
Mechanical valves, such as the bi-leaflet and tilting disk designs are often recommended
for their durability. Patients with mechanical heart valves however have a substantial risk
of systemic thrombotic occlusion(Jamieson, 1993). This is largely due to non-physiologic
surfaces and flow abnormalities created by the mechanical valves. Additionally, the
patients require lifelong anticoagulant therapy to counteract the thrombus(John & Liao,
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2013). Anticoagulant use is contraindicated in some heart valve patient sub-sections, such
as in pregnant women or women who may decide to have children later in life, because of
bleeding complications as well as risk of embryopathy and spontaneous abortions(Chan
W, Anand S, & Ginsberg JS, 2000). On the other hand, homografts and bio-prosthetic
tissue valves possess the advantage of not requiring chronic anticoagulant
therapy(Grunkemeier & Rahimtoola, 1990). However these valves are very prone to
fibrosis, calcification, degeneration, and immunogenic complications that can lead to
early failure(Sacks & Schoen, 2002). While mechanical, homograft and bio-prosthetic
valves have been used in patients for over 50 years and have made significant
improvements in patient morbidity, there is still a distinct need to overcome their
limitations as evidenced by the ten-year mortality rate following valve replacement,
which ranges from 30 to 55%(Edmunds et al., 1997).
Emerging, elastomer heart valves have been shown to be able to better re-create
the flow physics of native heart valves compared to mechanical valves, resulting in
preferable hemodynamic responses(Ramaswamy et al., 2013). They can be tailored to
mimic the mechanical properties of native tissue to withstand the coupled, flexural,
tensile and fluid-induced stresses, while remaining biocompatible and recapitulating
native valve motion. Such valves are likely to be suitable for straightforward massproduced in different sizes, while remaining cost effective. Research in the use of
polymer materials for the fabrication of tri-leaflet valves has been ongoing for over 50
years, but has faced substantial hurdles in the facilitation of adequate valve durability.
However, new methods in manufacturing and reinforcement of polymer materials have
resurrected the appeal of polymer materials for heart valve prosthesis application. One

24

such material that has found renewed interest is silicone. Unfortunately, silicone is prone
to structural failure which drastically limits its applicability for heart valve
prosthetics(Roe et al., 1966). Here, we proposed that silicone can be reinforced with
graphene nanoplatelets (GNPs) to promote its strength and durability for subsequent
valve prostheses development. Graphene is known for its high-strength(Lee et al., 2008).
Human cells also exhibit a minimal cytotoxic response to graphene(Santos et al., 2012).
Our primary objective therefore was to characterize the response of silicone substrates to
static and cyclical loading conditions with and without graphene reinforcement and, in
addition, to assess whether the graphene-silicone composites had altered cytotoxicity and
platelet adhesion properties relative to the silicone substrate alone.
Methods
Composite Material Fabrication
Four samples were created, one sample served as the control, which was prepared
without graphene, and the other three had final concentrations of 250mg, 75 mg, and 25
mg of graphene per liter of uncured silicone. GNP (XG Sciences Inc., Lansing, MI) with
~6-8 nm thickness, 120-150 m2/g surface area, and average particle diameters of 5 µm
were used. The graphene was mixed in acetone (Fisher Scientific, Pittsburg, PA) and
allowed to disperse in a sonication bath for 1 hour. The graphene-acetone solution was
then added to the base of the 2 part silicone kit (NuSil, Carpinteria, CA) and placed in a
vacuum for 15 minutes. The activator was added to the base; then the mixture was spread
evenly on a smooth non-stick surface and placed back in the vacuum for an additional 30
minutes, for removal of air bubbles. The samples were finally allowed to cure for at least
24 hours before use.
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Mechanical Testing
Static loading:
Mechanical test samples (n = 3 /group) were cut into strips approximately 15 x 6 x 0.25
(mm) from the fabricated bulk materials. Uni-axial tensile testing was carried out
(Electroforce 3200 test instrument, Bose Corporation, Eden Prairie, MN) using a 1000 g
load cell and a maximum crosshead movement of 11 at a displacement rate of 0.1 mm/s,
with an initial length of 10mm. In addition, the testing was conducted while the samples
were immersed in a water bath filled with 8 g/L of saline solution held at 37oC, to mimic
in vivo environmental conditions (Figure 8).

Figure 8: Set up for tensile testing showing the specimen grips and the test conditions,
including an envi-ronmental bath filled with 8 g/L saline solution (Bose Electroforce
system, Eden Prairie, MN). The temperature of the saline bath was maintained at 37oC
during testing.
Cyclic loading:
Fatigue properties of the samples (n = 3 /group) were subsequently determined
(Electroforce 3200, Bose Corporation). Original sample dimensions were ∼ 15 x 6 x 0.25
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(mm). As in the case of static testing, samples were again immersed in the saline bath
held at 37oC.
At a frequency of 0.05 Hz, the samples were cyclically stretched to 10 mm until failure
which was evidenced by sample breakage.
Cell Cytotoxicity
Cell Culture
Rat Adrenal Medulla Endothelial Cells (RAMECs) (Cellbiologics, Chicago, IL) were
seeded onto T-75 flasks (Fisher Scientific). The cells were cultured in the RAMECsupporting endothelial cell media (Sigma-Aldrich, St. Louis, MO) until passage three (3).
Once the cells were 90% confluent, they were trypsinzed from the flask using trypsin
(Fisher Scientific). The trypsinzed solution was then centrifuged for 5 minutes at 1700 g.
Furthermore, after centrifugation, the supernatant was removed and the pellet of cells
obtained was suspended in fresh media. Cells were counted using a haemocytometer and
desired quantity of cells were subsequently used for Cell Viability and cell proliferation
assays.
Cell Viability
To study the viability of RAMECs seeded on the silicone and silicone-graphene samples,
live mitochondrial and nuclear imaging of cells was performed (Live Mitochondrial and
Nuclear Labeling Kit, Invitrogen, Carlsbad, Ca) after 24 hours of cell culture. The
samples seeded with the RAMECs were incubated in 200nM MitoTracker Red
(mitochondrial staining) and 5µM Hoechst dye (nuclear staining) in endothelial cell
media for 15 minutes at 37°C. When the labeling procedure was completed, excess
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labeling solution was removed by washing with PBS twice. The sample surfaces were
subsequently observed under a fluorescence microscope (Olympus IX 81).
Cell Proliferation Assay
Cell proliferation on the silicone-graphene samples were determined using the
sulforhodamine B (SRB) Viability/Cytotoxity Assay Kit (Vitro Vivo Biotechnology,
Rockville, MD) which is based on the colorimeteric measurement of viable cellular
protein. RAMECs were seeded on the silicone and silicone-graphene surfaces (5mm X
5mm) with a cell density of 105 cells/mL. An SRB assay was performed on day 1, day 3
and day 7 (3 samples/group/time-point). In brief, cells were bound to the bottom of the
silicone and silicone-graphene substrates using trichloroacetic acid (Vitro Vivo
Biotechnology) which served as the fixative. Next the cells were stained using
sulforhodamine B dye (Vitro Vivo Biotechnology). The unbounded dye was then
removed using 1% acetic acid (Fisher Scientific). The dye bounded to the cellular protein
was extracted using 10mM Trizma (Vitro Vivo Biotechnology) base and the absorbance
was measured at a wavelength of 565nm using a micro-plate reader (Biotek Instruments
Inc., Winooski, Vermont).
Platelet Adhesion Characteristics
Silicone and silicone-graphene composite samples were cut into 1 cm x 1 cm squares.
Freshly collected whole porcine blood (1L, Mary’s Ranch Inc, Miami, FL) was
subsequently mixed with 667 mL of mepacrine dye (Quinacrine Dihydrochloride, Fisher
Scientific) and 300 mL of sodium citrate (Fisher Scientific) anti-coagulant. The samples
were then positioned into a custom blood flow loop available in our laboratory. The flow
loop was initially cleansed with deionized water for approximately 5 minutes, then
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washed with 1x phosphate buffered solution (PBS, Fisher Scientific) for approximately 5
minutes. The loop subsequently perfused the blood mixture for 35 minutes at a flow rate
of 679 mL/min. The samples were removed and rinsed with PBS, examined under the
microscope, and subsequently analyzed (ImageJ Software, National Institutes of
Health/NIH, Bethesda, MD) to quantify the number of platelets adhered to each of the
material surfaces.
Statistical Analysis
A one-way ANOVA (SPSS, IBM, Armonk, NY) was executed for all statistics conducted
in this study. When the analysis yielded a significant difference, a Dunnet post-hoc test
was performed to assess the significance of the graphene treated-groups relative to the
control (silicone-only samples). In all evaluations, a statistically significant difference
between groups was reported when p < 0.05.
Results
Gross Morphology
Microscopic visualization of the graphene-silicone samples revealed a randomized
distribution of dark graphene particles (Figure 9). Some of the particles appeared to have
aggregated in certain regions of the specimens. An increased presence of graphene
particles was clearly observed at the highest graphene concentration (250 mg/L) utilized,
compared to the other groups (0, 25 and 75 mg/L).
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Figure 9: Silicone-graphene material: (a) control containing only silicone. (b) 250 mg
GNP, (c) 75 mg GNP, and (d) 25 mg GNP of graphene per liter of uncured silicone.
Mechanical Testing
Static tensile testing revealed a similar stress-strain behavior (Figure 10A) for all groups
tested. The control sample had a Young’s modulus of 0.70 MPa; the samples containing
250mg, 75 mg, and 25mg of graphene per liter of uncured silicone had a Young’s
modulus of 0.85 MPa, 0.67 MPa, and 0.79 MPa, respectively. On the other hand, when a
cyclic flexural load was applied (0.05 Hz), the group with the highest concentration of
graphene (250 mg/L) was able to maintain its structural integrity for a significantly
longer duration (p < 0.05; Figure 10B). While the failure stresses of the silicone-only and
GNP-reinforced (250 mg/mL) were comparable in magnitude (~ 0.9 – 1 MPa range;
Figure 10C), the silicone specimens on average lasted 533 cycles compared to 1171
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cycles for the GNP-reinforced silicone composites (Figure 10B). The edges of the
samples that failed were inspected utilizing bright field microscopy (Figure 10C). The
graphene-containing specimens clearly possessed regions of GNP aggregates dispersed
throughout the material, whereas in the silicone-only specimens, a few air bubbles were
observed (Fig. 3C); air bubbles were not apparent in the GNP-reinforced silicone
samples.
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Figure 10: A) Mean stress-strain curve of silicone-graphene material (n = 3 specimens/group). B) Mean numbers of cyclic stretch
withstood by the samples before specimen failure (n = 3 specimens/group). Note that the samples were cyclically stretched from
rest to a maximum of 600% strain at a frequency of 0.05 Hz until the specimen broke. C) Stress versus number of cycles plot for
silicone-only and silicone-GNP (250 mg/mL). The sudden drop in stress demonstrates the point at which the specimen broke. The
plot also shows a corresponding view of the cross-section of the edge where breakage occurred. A few small air bubbles were
unavoidably present in the silicone-only samples. Introduction of GNP in the silicone matrix permitted an opportunity to serve as
a filler material, thereby eliminating the few void spaces within the substrate.
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Cytotoxicity
Viability verification demonstrated robust mitochondrial staining in the silicone-only as
well as in all the GNP-silicone groups (Figure 11A), indicating that the RAMECs were
alive and metabolically active after 24 hours of direct physical cell contact with the
material surfaces.
Positive cell proliferation occurred in all groups tested (Figure 11B). Compared to cell
numbers at day 1, a percentage increase in the relative survivability of RAMECs at day 7
was found as follows: silicone-only: 406%, 250 mg/L GNP-silicone: 762%, 75 mg/L
GNP-silicone: 692% and 25 mg/L GNP-silicone: 210%.

Figure 11: For the silicone-only (control) and silicone-GNP materials (25, 75 and 250
mg/mL), A) Fluorescence images showing cell viability after 24 hours or culture; red
color indicates mitochondrial staining and blue color is a counterstain of the nucleus.
GNP incorporation appeared to have no adverse effect on cell viability relative to the
controls since all groups demonstrated robust metabolic activity as shown by the large
degree of positive mitochondrial staining. B) Relative survivability of RAMECs after 1, 3,
and 7 days (n=3). All groups demonstrated positive proliferation over 1 week with the
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largest increased observed in the group containing 250 mg/ml of GNPs within the
silicone matrix.
Platelet Adhesion
Porcine whole blood flow exposure across the samples revealed no significant differences
found (p > 0.05) in the number of adhered platelets to the surface of the materials,
between any of the groups tested, i.e., GNP-Silicone: 250 mg/L, 75 mg/L, 25 mg/L and
Silicone –only; (Figure 12).

Figure 12: Mean number of platelets on sample surfaces after 35 minutes of exposure to
whole blood flow (n = 2 samples/group). Porcine blood was used and perfused across the
specimen surfaces at a flow rate of 679 mL/min. The groups tested comprised of siliconeonly, and GNP-silicone composites with the following densities of GNP: 250 mg, 75 mg,
and 25 mg of graphene per liter of uncured silicone

DISCUSSION
Prosthetic valve technologies to replace diseased heart valves represents a mature
technology with excellent prognosis for individuals otherwise in good health e.g. most
mechanical valves are functional for 20 to 30 years(Blot, 2005; Gott, Alejo, & Cameron,
2003). However, prosthetic valves are not without distinct limitations, many of which are
materials-dependent. For example, the artificial materials that are used to assemble
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mechanical valves are still predisposed to clots and thus require lifelong anti-coagulant
therapy; meanwhile bio-prosthetic valves consisting of xenograft, fixed-tissues deform
similar to native valve leaflets but tend to fail prematurely due to calcification, structural
breakdown and leaflet tearing. Additionally, many older patents (≥ 70 years) cannot be
treated for a valve replacement via a traditional route because of mortality risks
associated with open- heart surgery. We note that ∼ 50-60% of patients with replacement
valves either need a re-operation or die within ten years of valve implantation(A. Wang
& Bashore, 2009). For this reason, there is a move towards less invasive strategies for
valve replacement such as percutaneous valve approaches, which at the moment is only
considered in patients at high-risk for open heart surgery and which currently only
utilizes pericardium tissue valves. Further advancement of percutaneous valve
technologies is also likely to require the development of new valve prosthetics. Clearly,
the development of new prosthetic valves is necessary despite the efficacy of current
state-of-the-art heart valve implants.
Previously,

we

reported

on

the

functionality

of

a

novel

silicone

valve

prosthesis(Ramaswamy et al., 2013). This polymer valve was manufactured using a
proprietary manufacturing technique from a single silicone piece, thereby eliminating
potential weak zones along seam lines that would be created when assembling multiple
pieces. Hydrodynamically, the silicone valve exhibited less energy losses and
regurgitation volumes compared to bi-leaflet mechanical valves(Ramaswamy et al.,
2013). However, silicone is an inherently weak material and additional materials
processing is necessary to enhance the valve’s durability. To achieve this task, we
incorporated GNPs into the silicone matrix.
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GNPs presented themselves as dark aggregates within the silicone substrate (Fig. 2).
These dark regions were noticeably more common in specimens reinforced with 250
mg/L of GNPs in comparison to the smaller concentrations (25 and 75 mg/L). There was
a propensity for GNPs to clump into various-sized clusters that were in the order of up to
~ 50 µm. Interestingly the cytotoxic properties (Fig. 4) and hemocompatibility (Fig. 5) of
silicone remained unaltered (p > 0.05) after inclusion of GNPs even at the relatively
higher concentration of 250 mg/L. On the contrary, the relative survivability of the cells
was augmented by 762% which demonstrated significantly higher cell proliferation (p <
0.05) compared to the silicone-only controls, whose 1-week percent proliferation was
406%. These findings indicated that that the surface properties of the GNP-silicone
composites did not compromise cell properties, specifically viability and growth.
Mechanically, the GNP-silicone composites exhibited a similar constitutive response in
the tensile loading direction compared to the silicone-only controls. The samples were
stretched up to a strain of 1 and corresponding stresses at this strain value were found to
be within a narrow stress range of 410 to 484 KPA (Fig. 3A). The high distensibility of
silicone appeared to dominate during deformation with minimal interaction with the
embedded GNPs. We subsequently proceeded to cyclic stretch experiments at a low
frequency (0.05 Hz) and continued the testing until sample failure. Ironically, GNP
incorporation to the silicone matrix at 250 mg/mL permitted a substantial improvement in
the material’s response to cyclic stretch (Fig 3B). When the faces of the broken specimen
edges were examined, there was evidence of a few air bubbles or voids within the control
samples whereas these were absent in the GNP-silicone material (Fig. 3C). Similar to the
initial morphological examination (Fig. 2), at 250 mg/mL GNP concentration, the
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silicone substrate was infiltrated with GNP aggregates of various sizes which were found
to be smoothly integrated within the matrix. We interpret that beyond a critical density of
GNP such as at a concentration of 250 mg/mL, the cyclic stretching of the specimens
promoted recruitment of GNPs and interaction with the bulk silicone material. In so
doing, the GNP-silicone (250 mg/mL) specimen failure did not occur until an additional
638 cycles later (Fig. 3B) and was thus found to be significantly more durable than
silicone-alone (p < 0.05). This improvement in material response to cyclic loads as a
result of GNP incorporation is likely to be beneficial for elastomer-based valve prosthesis
development, particularly for utility in emerging percutaneous valve systems. However,
further confirmation at this stage is still necessary via hydrodynamic functionality
assessment of such a prosthesis.
In conclusion, we reinforced silicone with GNPs. The introduction of graphene to
silicone utilizing 250 mg/mL of GNP significantly improved (p < 0.05) the fatigue
properties of the elastomer. Silicone can be easily formed into tri-leaflet valve
configurations with leaflet dynamics depicting the movement of native heart valves;
however the elastomer inherently possesses poor tear strength and lacks durability which
has limited its utility for heart valve prosthesis application. Our initial findings here
suggest that GNPs can augment the durability of the silicone matrix while still allowing
for sufficient distensibility, potentially resembling native valve leaflets. This work
provides the foundation for preparing tri-leaflet silicone-graphene heart valves for
hydrodynamic functionality testing, which will be the next step in this research.
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Chapter 5 AIM 2: Ecm Valves
Background
We have collaborated with cardiac surgeons at Joe DiMaggio Children’s Hospital to
evaluate a long-term solution for children with heart valve defects. Mechanical valves
and bioprosthetics substitutes are problematic for children. There is a lack of appropriate
sizes for implants in small children and neonates. As the child grows, the mechanical
valve becomes mismatched and will require re-replacement. The child will also require
strict anticoagulation therapy to mitigate the lifetime risk of thromboembolic and
bleeding complications
Although the bioprosthetics do not require anticoagulation therapy, the tissue is not living
and will not grow with the child. The durability of the bioprosthetic in pediatric patients
is limited due to the high risk of accelerated structural valve degeneration and early
calcification.
The Ross procedure remains achoice for aortic valve replacement in infants and children.
However, the operation is a technically demanding procedure and requires the surgeons
to operate on and replace both the pulmonary valve and the aortic valve.
The extracellular matrix (ECM) material that we are investigating in this study has the
potential to recruit cells from the surrounding area to become living tissue. The ECM
derives from the porcine small intestinal submucosa. If the valve leaflets could be
replaced with such a tissue, the whole valve may be able to grow with the patient (via in
vivo tissue remodeling processes) and not require anticoagulation therapy, while the
maintaining good durability and hydrodynamic performance.

38

The surgeons have already implanted these leaflets into pediatric patents in
compassionate care situations and have shown promising results. In essence the valves
have thus far functioned flawlessly (at the time of this thesis, for ∼ 1 year after valve
implantation). In this study, with are characterizing the acute in vitro performance of
these valves in the aortic position.
Method
Valves
Fresh porcine hearts were harvested from a USDA approved slaughterhouse (Mary’s
Ranch Inc, Miami, FL) and the aortic root were isolated using a scalpel. The aortic valve
and the aorta conduit were separated and stored in PBS solution mixed with a protease
inhibitor cocktail (Sigma-Aldrich).
The aortic root and conduit were provided to cardiac surgeons at Joe DiMaggio
Children’s Hospital to construct the valves. To create the aortic valve, the native leaflets
in the aortic root were removed. The ECM (CorMatrix, Roswell, GA) was cut using the
pattern from patent 5,716,399 (Figure 13). The ECM material was submerged in saline to
hydrate it. The ECM material was then sutured in the aortic root around the annulus and
the wall root where the original leaflets met.
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Figure 13: Pattern used for aortic leaflets. (Love, 1998)

Valve Testing
Valve testing was performed using a pulse duplicator (Vivitro Labs, Vancover, Canada),
that simulates the left side of the heart (left ventricle and left atrium). The valves were
positioned into the base of the valve holders and sutured to the holder around the annulus
and sino-tubular junction (STJ) of the valve. The valve holder was then inserted into the
pulse duplicator and the system was checked for leaks. Upon verification that the system
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was leak-free, hydrodynamic Evaluation was conducted using the following parameters,
(see Table 2).
Table 2: Parameters for hydrodynamic testing
Parameter

Setting

Heart Rate

70 bpm

Flow Waveform

S35 (35% systolic)

Stroke Rate

80 ml/stroke

Testing Fluid

0.9% Saline

Calculations
Data was calculated using the following equations (1-3) where Q is flow (ml/s); ΔP is the
mean pressure difference(mmHg); ρ is the density of the test fluid (g/cm3);v is the
velocity of the fluid; A aorta is the cross sectional area of the aorta; and SV is the stroke
volume. Figure 14 shows a representative flow and pressure waveform used to identify
the different pressure and flow points.
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Figure 14 - schematic representation of the positive pressure period of an aortic forward flow interval from ISO-5840

Results and Discussions
Hydrodynamic testing results showed that the ECM valve preformed very close to the
commercially available Medtronic freestyle bio-prosthetic valve. The pressure profiles as
seen in Figure 15 are very similar. The aortic pressure profiles during systole (when the
valve is fully open and blood is flowing through the aortic valve) are near identical. There
were slight differences between ECM and bioprosthetic valve aortic pressure
profilesduring diastole, although the overall shape of the pressure curves remained very
similar.
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ECM vs Bioprosthetic Valves
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Figure 15- Aortic and Ventricular pressure profiles for the ECM and Medtronic
bioprosthetic

The flow profile as seen Figure 16, also shows that the valves performed similarly from a
flow standpoint. The bioprosthetic valve did show significantly higher leakage during
diastole (P < 0.05), but the RMS flow (which is calculated during forward flow) was not
found to be significantly different from the ECM valves (P > 0.05). This type of leakage
could have occurred as a result of fit mismatches between the bioprosthetic valve and the
testing fixture leading to small amounts of paravalvular leakage.
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Figure 16- Flow rate of ECM and Medtronic Bioprosthetic valve

The summary of the hydrodynamic testing is shown in Table 3. The mean pressure drop,
RMS Flow, and EOA were all close and not statistically significant (P > 0.05) when a
nonparametric Mood Median test was performed. The Mood Median test was selected
due to the small sample sizes. A traditional t-test was not used since the sample sizes are
too small to determine whether the data is normally disturbed. The regurgitation fraction
is higher (p < 0.05) for the bioprosthetic valve, mostly likely due to paravalular leakage.
The systolic energy loss was significantly (p< 0.05) higher for the ECM valve, and may
indicate an area of concern in the long-term for the ECM valve. However, more testing
and verification with clinical results are needed to confirm this finding.
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Table 3 - Summary of hydrodynamic results. * denote statistically significant (P < 0.05)
Regurgitation
Systolic
Fraction
Energy Loss
[%]*
[mJ]*

Aortic Valves

ΔP
[mmHg]

Q rms [ml/s]

EOA
[cm2]

PSIS ECM
(n=3)

24.0 ± 2.4

239.9 ±
44.4

0.96 ±
0.21

13.8 ± 9.8

Bioprosthetic
(n=2)

18.1 ± 1.9

244.4 ± 3.6

1.12 ±
0.08

51.3 ± 0.8

36.4 ± 19.1
2.9 ± 0.7

All these results indicate that the valve created with the ECM material performed very
similarly to the commercially available Medtronic Freestyle valve. We would expect
good performance if these valves are implanted to patients. The hydrodynamic
performance of the ECM material combined with its ability to cellularize after
implantation suggests that these valves would benefit infants and young patients with
critical valve disease, due to the ability to support somatic growth. Of note, the EOA that
was calculated for the commercially available bioprosthetic that we tested is within the
manufacturer’s product specifications (Del Rizzo & Abdoh, 1998). Hence this verified
the accuracy of our measurements.

Chapter 6 Limitations and Future Studies
The two aims of my research have investigated different flexible materials for aortic
valve applications. The first aim has looked at a novel graphene reinforced silicone
material that is more durability than silicone on its own and the second aim deals with a
novel use for the ECM material. Both these materials provide some advantages over
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materials currently being used in commercially available products and solve some of their
inherent problems. A lot of work still needs to be done to completely understand these
materials when used for aortic valve applications.
Graphene Reinforced Silicone
Aim 1 of this study has shown that graphene is able to reinforce the silicone matrix and
improve its durability. This opens the potential for use as a new material for heart valves.
The cyclic fatigue was conducted at a rate of 0.05 Hz due to limitation of the testing
hardware. In physiological conditions, the material would experience of around 1.2 Hz
due to the opening and closing of the heart valve. Even though frequency was much
lower than what would be experience by an implanted heart valve, the strains used in the
study were many time greater than the strain the heart valve would ever experience.
Further studies are needed to evaluate the graphene reinforced silicone for use as a
material for heart valve application. Like native silicone, the material could still be easily
manufactured into different shapes. A heart valve could be created using injection
molding to predict the hydrodynamic properties and effectiveness of such a valve after
implantation. Thin sheets of the silicone graphene material could also be produced and
combined with self-explaining nitinol stent to study it’s potential for transcatheter
applications.
The preliminary studies have shown good biocompatibility and low cytotoxicity.
However, further studies are needed to completely characterize the safety of graphenereinforced material. An animal study would be able to show how the surrounding tissue
will interact with the material.
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ECM Valves
The ECM valves have shown good hydrodynamic properties and acute performance after
the valve is implanted. The hydrodynamic testing was performed using parameters for an
adult. The valves that have been implanted so far have been in children. Also, this study
only looked at acute performance of the valve.
The valves still need to be further characterized. Long-term studies need to be conducted
to observe how the valve changes over time. Durability of the valve also needs to be
assessed. Accelerated wear testing would be able to show how the ECM leaflets would
survive hundreds of millions of cycles under pulsatile conditions, i.e. if the valves will
remain functional from a structural standpoint, over several years.
Further studies are needed to investigate how the ECM material is being cellularized after
it is implanted into the valve, the rate of its degradation and if it does in fact
accommodate somatic growth. Longitudinal histological assessment from in vivo studies
will need to be conducted to see what type of cells proliferate in the ECM scaffold space,
the extent of scaffold degradation and the type of matrix components being expressed
extracellularly.
Since the ECM material is already decellularized, it has the potential to act as a tissue
engineering scaffold. Cells from the target patient would be taken and used to seed the
ECM material to form living tissue and then made into a heart valve. The valve would
have living tissue, so it would be much closer to a native valve. Since the tissue is made
with the patients one cells, the body would not reject it. The patient would not need to
take any immunosuppressant to prevent rejection of the tissue. However whether in vitro
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cell-seeding (e.g. with stem cells) would provide a significant advancement over the
acellular ECM material for valve replacement purposes is not known at this time.
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